AstraZeneca has announced that the U.S. FDA has given its go ahead for the company’s Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults. The drug was approved roughly two months after being granted a Breakthrough Therapy Designation by the U.S. FDA in collaboration with drug watchdogs in Canada and Australia. The decision to also approve Calquence for the treatment of small lymphocytic lymphoma, a similar disease, will pit the AstraZeneca drug against AbbVie and Johnson & Johnson’s established CLL treatment Imbruvica. Learn More